Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation

Ahmet Arac, Sara E. Brownell, Jonathan B. Rothbard, Charlene Chen, Rose M. Ko, Marta P. Pereira, Gregory W. Albers, Lawrence Steinman, Gary K. Steinberg

Research output: Contribution to journalArticlepeer-review

104 Scopus citations

Abstract

Tissue plasminogen activator is the only treatment option for stroke victims; however, it has to be administered within 4.5 h after symptom onset, making its use very limited. This report describes a unique target for effective treatment of stroke, even 12 h after onset, by the administration of αB-crystallin (Cryab), an endogenous immunomodulatory neuroprotectant. In Cryab -/- mice, there was increased lesion size and diminished neurologic function after stroke compared with wild-type mice. Increased plasma Cryab was detected after experimental stroke in mice and after stroke in human patients. Administration of Cryab even 12 h after experimental stroke reduced both stroke volume and inflammatory cytokines associated with stroke pathology. Cryab is an endogenous anti-inflammatory and neuroprotectant molecule produced after stroke, whose beneficial properties can be augmented when administered therapeutically after stroke.

Original languageEnglish (US)
Pages (from-to)13287-13292
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume108
Issue number32
DOIs
StatePublished - Aug 9 2011
Externally publishedYes

Keywords

  • Immune system
  • Ischemic stroke

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation'. Together they form a unique fingerprint.

Cite this